Ken Perry

1.3k total citations · 1 hit paper
17 papers, 974 citations indexed

About

Ken Perry is a scholar working on Cellular and Molecular Neuroscience, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Ken Perry has authored 17 papers receiving a total of 974 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cellular and Molecular Neuroscience, 7 papers in Psychiatry and Mental health and 3 papers in Molecular Biology. Recurrent topics in Ken Perry's work include Neuroscience and Neuropharmacology Research (6 papers), Neurotransmitter Receptor Influence on Behavior (6 papers) and Attention Deficit Hyperactivity Disorder (5 papers). Ken Perry is often cited by papers focused on Neuroscience and Neuropharmacology Research (6 papers), Neurotransmitter Receptor Influence on Behavior (6 papers) and Attention Deficit Hyperactivity Disorder (5 papers). Ken Perry collaborates with scholars based in United States, Poland and Singapore. Ken Perry's co-authors include Ray W. Fuller, Lee A. Phebus, Frank P. Bymaster, Richard Dodel, Yansheng Du, Zhizhong Ma, David L. Nelson, Eyassu Chernet, Feng Gao and Suizhen Lin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Neurology and Annals of the New York Academy of Sciences.

In The Last Decade

Ken Perry

17 papers receiving 958 citations

Hit Papers

Minocycline prevents nigrostriatal dopaminergic neurodege... 2001 2026 2009 2017 2001 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease
    2001 655 citations Yansheng Du, Zhizhong Ma et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ken Perry United States 11 485 351 299 236 125 17 974
Milica Cerovic Italy 16 468 1.0× 194 0.6× 264 0.9× 362 1.5× 158 1.3× 23 973
Wei Dong Le United States 15 485 1.0× 286 0.8× 426 1.4× 334 1.4× 155 1.2× 20 1.1k
Mei Yu China 23 442 0.9× 268 0.8× 268 0.9× 445 1.9× 136 1.1× 39 1.2k
Margaret Sutherland United States 15 438 0.9× 135 0.4× 192 0.6× 398 1.7× 132 1.1× 24 994
Emiliano Fernández‐Villalba Spain 20 429 0.9× 470 1.3× 505 1.7× 320 1.4× 208 1.7× 48 1.3k
Silvia Buervenich Sweden 13 430 0.9× 108 0.3× 187 0.6× 326 1.4× 97 0.8× 13 987
O. V. Godukhin Russia 17 606 1.2× 201 0.6× 88 0.3× 350 1.5× 90 0.7× 57 915
Heather Booth United Kingdom 15 489 1.0× 313 0.9× 505 1.7× 567 2.4× 366 2.9× 17 1.4k
Mélanie Bourque Canada 19 544 1.1× 144 0.4× 380 1.3× 272 1.2× 108 0.9× 40 1.2k
Marie‐Catherine Boll Mexico 20 428 0.9× 209 0.6× 482 1.6× 353 1.5× 214 1.7× 48 1.1k

Countries citing papers authored by Ken Perry

Since Specialization
Citations

This map shows the geographic impact of Ken Perry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Perry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Perry more than expected).

Fields of papers citing papers by Ken Perry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Perry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Perry. The network helps show where Ken Perry may publish in the future.

Co-authorship network of co-authors of Ken Perry

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Perry. A scholar is included among the top collaborators of Ken Perry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Perry. Ken Perry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Johnson, Anna E., et al.. (2022). SARM1 knockout does not rescue neuromuscular phenotypes in a Charcot‐Marie‐Tooth disease Type 1A mouse model. Journal of the Peripheral Nervous System. 27(1). 58–66. 5 indexed citations
2.
Roda, Ricardo H., David Bargiela, Weiran Chen, et al.. (2021). Large Mitochondrial DNA Deletions in HIV Sensory Neuropathy. Neurology. 97(2). e156–e165. 5 indexed citations
3.
DiSalvo, Betsy, et al.. (2013). Workifying games. 317–322. 29 indexed citations
4.
Brus, Ryszard, Richard M. Kostrzewa, Przemysław Nowak, Ken Perry, & John P. Kostrzewa. (2003). Ontogenetic quinpirole treatments fail to prime for D2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats. Neurotoxicity Research. 5(5). 329–338. 25 indexed citations
5.
Johnson, Kirk W., George G. Nomikos, Richard W. Davis, et al.. (2003). In Vivo Characterization of Changes in Glycine Levels Induced by GlyT1 Inhibitors. Annals of the New York Academy of Sciences. 1003(1). 412–414. 11 indexed citations
6.
Bymaster, F.P., Donald R. Gehlert, D. Nelson, et al.. (2002). Atomoxetine increases cortical levels of norepinephrine and dopamine: A proposed mechanism of action in ADHD. European Neuropsychopharmacology. 12. 418–418. 1 indexed citations
7.
Du, Yansheng, Zhizhong Ma, Suizhen Lin, et al.. (2001). Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proceedings of the National Academy of Sciences. 98(25). 14669–14674. 655 indexed citations breakdown →
8.
Perry, Ken, et al.. (2001). Habitat monitoring for conservation management and reporting. 2 indexed citations
9.
Shannon, H E, F.P. Bymaster, Walter Offen, et al.. (1998). Muscarinic agents: A new approach to the treatment of psychosis. Schizophrenia Research. 29(1-2). 158–159. 2 indexed citations
10.
11.
Brus, R, et al.. (1996). The effect of prolonged administration of lithium on the level of dopamine D2 receptor mRNA in the rat striatum and nucleus accumbens. Acta Neurobiologiae Experimentalis. 56(1). 21–28. 1 indexed citations
12.
Brus, R, et al.. (1994). Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment.. Journal of Pharmacology and Experimental Therapeutics. 268(1). 231–237. 51 indexed citations
13.
Brus, Ryszard, et al.. (1994). Proposed animal model of attention deficit hyperactivity disorder. Brain Research Bulletin. 34(2). 161–167. 58 indexed citations
14.
Kostrzewa, Richard M., Ryszard Brus, Ken Perry, & Ray W. Fuller. (1993). Age-dependence of a 6-hydroxydopamine lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Developmental Brain Research. 76(1). 87–93. 34 indexed citations
15.
Gong, Li, Richard M. Kostrzewa, Ken Perry, & Ray W. Fuller. (1993). Dose-related effects of a neonatal 6-OHDA lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Developmental Brain Research. 76(2). 233–238. 38 indexed citations
16.
Perry, Ken, et al.. (1993). Possible involvement of dopamine in the long-term serotonin depletion by p-chloroamphetamine and beta,beta-difluoro-p-chloroamphetamine in rats.. Journal of Pharmacology and Experimental Therapeutics. 267(1). 417–424. 10 indexed citations
17.
Fuller, Ray W., Ken Perry, & Bryan B. Molloy. (1975). EFFECT OF 3-(p-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3-PHENYLPROPYLAMINE ON THE DEPLETION OF BRAIN SEROTONIN BY 4-CHLOROAMPHETAMINE. Journal of Pharmacology and Experimental Therapeutics. 193(3). 796–803. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Milica Cerovic Breakdown of academic impact, for papers by Wei Dong Le Breakdown of academic impact, for papers by Mei Yu Breakdown of academic impact, for papers by Margaret Sutherland Breakdown of academic impact, for papers by Emiliano Fernández‐Villalba Breakdown of academic impact, for papers by Silvia Buervenich Breakdown of academic impact, for papers by O. V. Godukhin Breakdown of academic impact, for papers by Heather Booth Breakdown of academic impact, for papers by Mélanie Bourque Breakdown of academic impact, for papers by Marie‐Catherine Boll
Rankless by CCL
2026